References

Small-molecule inhibitors, immune checkpoint inhibitors, and more: FDA-approved novel therapeutic drugs for solid tumors from 1991 to 2021

10.1186/s13045-022-01362-9 · 2022 · External reference

Review of precision cancer medicine: evolution of the treatment paradigm

10.1016/j.ctrv.2020.102019 · 2020 · External reference

Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia

10.1056/nejm200104053441401 · 2001 · External reference

Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib

10.1056/nejmoa040938 · 2004 · External reference

Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma

10.1056/nejmoa0810699 · 2009 · External reference

Impact of precision medicine in diverse cancers: a meta-analysis of phase II clinical trials

10.1200/jco.2015.61.5997 · 2015 · External reference

Integrating next-generation sequencing into clinical oncology: strategies, promises and pitfalls

10.1136/esmoopen-2016-000094 · 2016 · External reference

Pan-cancer efficacy of vemurafenib in BRAF (V600)-mutant non-melanoma cancers

10.1158/2159-8290.cd-19-1265 · 2020 · External reference

Tumor-agnostic precision medicine from the AACR GENIE database: clinical implications

10.1158/1078-0432.ccr-23-0090 · 2023 · External reference

Personalized immunotherapy in cancer precision medicine

2021 · External reference

Tumor mutational burden as an independent predictor of response to immunotherapy in diverse cancers

10.1158/1535-7163.mct-17-0386 · 2017 · External reference

PD-L1 as a biomarker of response to immune-checkpoint inhibitors

10.1038/s41571-021-00473-5 · 2021 · External reference

Multi-institutional randomized phase ii trial of gefitinib for previously treated patients with advanced non–small-cell lung cancer

10.1200/jco.2003.10.038 · 2003 · External reference

Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR

10.1056/nejmoa0909530 · 2010 · External reference

U.S. Food and Drug Administration approval summary: erlotinib for the first-line treatment of metastatic non-small cell lung cancer with epidermal growth factor receptor exon 19 deletions or exon 21 (L858R) substitution mutations

10.1634/theoncologist.2014-0089 · 2014 · External reference

FDA approval summary: crizotinib for the treatment of metastatic non-small cell lung cancer with anaplastic lymphoma kinase rearrangements

10.1634/theoncologist.2014-0241 · 2014 · External reference

Phase II study of receptor-enhanced chemosensitivity using recombinant humanized anti-p185HER2/neu monoclonal antibody plus cisplatin in patients with HER2/neu-overexpressing metastatic breast cancer refractory to chemotherapy treatment

10.1200/jco.1998.16.8.2659 · 1998 · External reference

FDA approval summary: entrectinib for the treatment of NTRK gene fusion solid tumors

10.1158/1078-0432.ccr-20-2771 · 2021 · External reference

FDA approval summary: pembrolizumab for the treatment of microsatellite instability-high solid tumors

10.1158/1078-0432.ccr-18-4070 · 2019 · External reference

FDA approval summary: pembrolizumab for the treatment of tumor mutational burden-high solid tumors

10.1158/1078-0432.ccr-21-0327 · 2021 · External reference

Current Insights on the treatment of anaplastic lymphoma kinase-positive metastatic non-small cell lung cancer: focus on brigatinib

2022 · External reference

Larotrectinib in patients with TRK fusion-positive solid tumours: a pooled analysis of three phase 1/2 clinical trials

10.1016/s1470-2045(19)30856-3 · 2020 · External reference

Delivering precision oncology to patients with cancer

10.1038/s41591-022-01717-2 · 2022 · External reference

Liquid versus tissue biopsy for detecting acquired resistance and tumor heterogeneity in gastrointestinal cancers

10.1038/s41591-019-0561-9 · 2019 · External reference

Detection of K-ras gene mutation by liquid biopsy in patients with pancreatic cancer

10.1002/cncr.29364 · 2015 · External reference

Real-world data from a molecular tumor board demonstrates improved outcomes with a precision N-of-One strategy

10.1038/s41467-020-18613-3 · 2020 · External reference

Tamoxifen: a most unlikely pioneering medicine

10.1038/nrd1031 · 2003 · External reference

Adjuvant trastuzumab: a milestone in the treatment of HER-2-positive early breast cancer

10.1634/theoncologist.11-90001-4 · 2006 · External reference

Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer

10.1056/nejmoa052306 · 2005 · External reference

Adjuvant pertuzumab and trastuzumab in early her2-positive breast cancer

10.1056/nejmoa1703643 · 2017 · External reference

Event-free survival with pembrolizumab in early triple-negative breast cancer

10.1056/nejmoa2112651 · 2022 · External reference

Adjuvant pembrolizumab after nephrectomy in renal-cell carcinoma

10.1056/nejmoa2106391 · 2021 · External reference

Adjuvant nivolumab versus placebo in muscle-invasive urothelial carcinoma

10.1056/nejmoa2034442 · 2021 · External reference

Pembrolizumab versus placebo as adjuvant therapy for completely resected stage IB–IIIA non-small-cell lung cancer (PEARLS/KEYNOTE-091): an interim analysis of a randomised, triple-blind, phase 3 trial

10.1016/s1470-2045(22)00518-6 · 2022 · External reference

Neoadjuvant nivolumab plus chemotherapy in resectable lung cancer

10.1056/nejmoa2202170 · 2022 · External reference

Adjuvant atezolizumab after adjuvant chemotherapy in resected stage IB-IIIA non-small-cell lung cancer (IMpower010): a randomised, multicentre, open-label, phase 3 trial

10.1016/s0140-6736(21)02098-5 · 2021 · External reference

Clinical trial design in the era of precision medicine

10.1186/s13073-022-01102-1 · 2022 · External reference

Systematic review of basket trials, umbrella trials, and platform trials: a landscape analysis of master protocols

10.1186/s13063-019-3664-1 · 2019 · External reference

Tumour-agnostic efficacy and safety of selpercatinib in patients with RET fusion-positive solid tumours other than lung or thyroid tumours (LIBRETTO-001): a phase 1/2, open-label, basket trial

10.1016/s1470-2045(22)00541-1 · 2022 · External reference

Dabrafenib and trametinib in patients with tumors with BRAFV600E mutations: results of the NCI-MATCH Trial Subprotocol H

10.1200/jco.20.00762 · 2020 · External reference

Dabrafenib plus trametinib in patients with BRAFV600E-mutant low-grade and high-grade glioma (ROAR): a multicentre, open-label, single-arm, phase 2, basket trial

10.1016/s1470-2045(21)00578-7 · 2022 · External reference

Personalized medicine in a phase I clinical trials program: the MD Anderson Cancer Center initiative

10.1158/1078-0432.ccr-12-1627 · 2012 · External reference

Long-term overall survival and prognostic score predicting survival: the IMPACT study in precision medicine

10.1186/s13045-019-0835-1 · 2019 · External reference

The NCI-MATCH trial: lessons for precision oncology

10.1038/s41591-023-02379-4 · 2023 · External reference

Molecular landscape and actionable alterations in a genomically guided cancer clinical trial: national cancer institute molecular analysis for therapy choice (NCI-MATCH)

10.1200/jco.19.03010 · 2020 · External reference

Benchmark of actionability

2021 · External reference

N-of-1 trials in cancer drug development

10.1158/2159-8290.cd-22-1377 · 2023 · External reference

Molecular profiling of cancer patients enables personalized combination therapy: the I-PREDICT study

10.1038/s41591-019-0407-5 · 2019 · External reference

Molecular profiling of advanced malignancies guides first-line N-of-1 treatments in the I-PREDICT treatment-naïve study

10.1186/s13073-021-00969-w · 2021 · External reference

Precision oncology: the UC San Diego Moores Cancer Center PREDICT experience

10.1158/1535-7163.mct-15-0795 · 2016 · External reference

Precision medicine-based therapies in advanced colorectal cancer: The University of California San Diego Molecular Tumor Board experience

10.1002/1878-0261.13202 · 2022 · External reference

Abemaciclib combined with endocrine therapy for the adjuvant treatment of hr+, her2-node-positive, high-risk, early breast cancer (monarchE)

10.1200/jco.20.02514 · 2020 · External reference

Overall Survival with osimertinib in resected EGFR-mutated NSCLC

10.1056/nejmoa2304594 · 2023 · External reference

Olaparib for metastatic breast cancer in patients with a germline BRCA mutation

10.1056/nejmoa1706450 · 2017 · External reference

FDA approval summary: olaparib monotherapy or in combination with bevacizumab for the maintenance treatment of patients with advanced ovarian cancer

10.1002/onco.13551 · 2021 · External reference

Maintenance olaparib for germline BRCA-mutated metastatic pancreatic cancer

10.1056/nejmoa1903387 · 2019 · External reference

Olaparib for metastatic castration-resistant prostate cancer

10.1056/nejmoa1911440 · 2020 · External reference

Rucaparib in men with metastatic castration-resistant prostate cancer harboring a BRCA1 or BRCA2 gene alteration

10.1200/jco.20.01035 · 2020 · External reference

Adjuvant olaparib for patients with BRCA1- or BRCA2-mutated breast cancer

10.1056/nejmoa2105215 · 2021 · External reference

Overall survival in the OlympiA phase III trial of adjuvant olaparib in patients with germline pathogenic variants in BRCA1/2 and high-risk, early breast cancer

10.1016/j.annonc.2022.09.159 · 2022 · External reference

Effect of pembrolizumab plus neoadjuvant chemotherapy on pathologic complete response in women with early-stage breast cancer: an analysis of the ongoing phase 2 adaptively randomized I-SPY2 Trial

10.1001/jamaoncol.2019.6650 · 2020 · External reference

I-SPY 2: an adaptive breast cancer trial design in the setting of neoadjuvant chemotherapy

10.1038/clpt.2009.68 · 2009 · External reference

Developing a virtual equity hub: adapting the tumor board model for equity in cancer care

10.1093/oncolo/oyac069 · 2022 · External reference

A virtual molecular tumor board to improve efficiency and scalability of delivering precision oncology to physicians and their patients

10.1093/jamiaopen/ooz045 · 2019 · External reference

A fully virtual and nationwide molecular tumor board for gynecologic cancer patients: the virtual experience of the MITO cooperative group

10.1136/ijgc-2022-003425 · 2022 · External reference

Genomic landscape and clinical utility in Korean advanced pan-cancer patients from prospective clinical sequencing: K-MASTER program

10.1158/2159-8290.cd-21-1064 · 2022 · External reference

Value of a molecular screening program to support clinical trial enrollment in Asian cancer patients: The Integrated Molecular Analysis of Cancer (IMAC) Study

10.1002/ijc.31091 · 2018 · External reference

Clinical utility of circulating tumor DNA sequencing in advanced gastrointestinal cancer: SCRUM-Japan GI-SCREEN and GOZILA studies

10.1038/s41591-020-1063-5 · 2020 · External reference

Think globally, act locally: globalizing precision oncology

10.1158/2159-8290.cd-22-0024 · 2022 · External reference

Global Inequities in precision medicine and molecular cancer research

10.3389/fonc.2018.00346 · 2018 · External reference

Incidental germline variants in 1000 advanced cancers on a prospective somatic genomic profiling protocol

10.1093/annonc/mdw018 · 2016 · External reference

Germline analysis from tumor-germline sequencing dyads to identify clinically actionable secondary findings

10.1158/1078-0432.ccr-16-0015 · 2016 · External reference

Germline variants in targeted tumor sequencing using matched normal DNA

10.1001/jamaoncol.2015.5208 · 2016 · External reference

When should tumor genomic profiling prompt consideration of germline testing?

10.1200/jop.19.00201 · 2019 · External reference

Functional precision cancer medicine-moving beyond pure genomics

10.1038/nm.4389 · 2017 · External reference

Functional precision oncology: testing tumors with drugs to identify vulnerabilities and novel combinations

10.1016/j.ccell.2021.12.004 · 2022 · External reference

Rational combinations of targeted cancer therapies: background, advances and challenges

10.1038/s41573-022-00615-z · 2023 · External reference

A review of mechanisms of resistance to immune checkpoint inhibitors and potential strategies for therapy

2020 · External reference

National cancer institute combination therapy platform trial with molecular analysis for therapy choice (ComboMATCH)

10.1158/1078-0432.ccr-22-3334 · 2023 · External reference

Efficacy and safety of trastuzumab deruxtecan (T-DXd) in patients (pts) with HER2-expressing solid tumors: DESTINY-PanTumor02 (DP-02) interim results

10.1200/jco.2023.41.17_suppl.lba3000 · 2023 · External reference

Lutetium-177–PSMA-617 for metastatic castration-resistant prostate cancer

10.1056/nejmoa2107322 · 2021 · External reference

Rationale and design of the targeted agent and profiling utilization registry (TAPUR) study

2018 · External reference

Pembrolizumab in patients with metastatic breast cancer with high tumor mutational burden: results from the targeted agent and profiling utilization registry (TAPUR) Study

10.1200/jco.20.02923 · 2021 · External reference

Pertuzumab plus trastuzumab in patients with endometrial cancer with ERBB2/3 amplification, overexpression, or mutation: results from the TAPUR study

10.1200/po.22.00609 · 2023 · External reference

Precision medicine: preliminary results from the Initiative for Molecular Profiling and Advanced Cancer Therapy 2 (IMPACT2) study

10.1038/s41698-021-00159-2 · 2021 · External reference

From tissue-agnostic to N-of-one therapies: (R)evolution of the precision paradigm

10.1016/j.trecan.2020.08.009 · 2021 · External reference

Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years’ adjuvant treatment for breast cancer

10.1016/s0140-6736(04)17666-6 · 2005 · External reference

Trastuzumab emtansine for residual invasive HER2-positive breast cancer

10.1056/nejmoa1814017 · 2018 · External reference

PD-1 blockade in mismatch repair-deficient, locally advanced rectal cancer

10.1056/nejmoa2201445 · 2022 · External reference

Adjuvant dabrafenib plus trametinib in stage III BRAF-MUTATED MELAnoma

10.1056/nejmoa1708539 · 2017 · External reference

Maintenance olaparib in patients with newly diagnosed advanced ovarian cancer

10.1056/nejmoa1810858 · 2018 · External reference